These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 37454572)
1. Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease. Peng H; Chen S; Wu S; Shi X; Ma J; Yang H; Li X J Neurol Sci; 2023 Aug; 451():120730. PubMed ID: 37454572 [TBL] [Abstract][Full Text] [Related]
2. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824 [TBL] [Abstract][Full Text] [Related]
3. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome. Wang R; Sun H; Ren H; Wang G Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494 [TBL] [Abstract][Full Text] [Related]
4. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains. Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884 [TBL] [Abstract][Full Text] [Related]
6. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. O'Hara DM; Kalia SK; Kalia LV Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011 [TBL] [Abstract][Full Text] [Related]
8. Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease. Ma LY; Liu GL; Wang DX; Zhang MM; Kou WY; Feng T ACS Chem Neurosci; 2019 Feb; 10(2):812-823. PubMed ID: 30714719 [TBL] [Abstract][Full Text] [Related]
9. Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents. Sato H; Kato T; Arawaka S Mol Neurobiol; 2015 Aug; 52(1):226-35. PubMed ID: 25143237 [TBL] [Abstract][Full Text] [Related]
10. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review. Rodger AT; ALNasser M; Carter WG Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200 [TBL] [Abstract][Full Text] [Related]
11. Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance. Cui H; Wang W; Zheng X; Xia D; Liu H; Qin C; Tian H; Teng J J Mol Neurosci; 2021 Dec; 71(12):2500-2513. PubMed ID: 33772424 [TBL] [Abstract][Full Text] [Related]
12. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment. Kalsoom I; Wang Y; Li B; Wen H Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991 [TBL] [Abstract][Full Text] [Related]
13. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease. Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353 [TBL] [Abstract][Full Text] [Related]
14. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208 [TBL] [Abstract][Full Text] [Related]